Press Releases

13 December 2021

Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment 

30 September 2021

Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption

29 September 2021

Acacia Pharma Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets

16 September 2021

Acacia Pharma Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation

02 September 2021

Acacia Pharma to Host Webinar with Key Opinion Leaders to Discuss the Hospital User Experience with Barhemsys® and Byfavo®

01 July 2021

Acacia Pharma Announces Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the US

29 June 2021

Results of Annual General Meeting

25 May 2021

Acacia Pharma to Participate in Jefferies Virtual Healthcare Conference

19 May 2021

Acacia Pharma Appoints Debra Hussain as Chief Commercial Officer

04 May 2021

Acacia Pharma Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital

21 April 2021

Acacia Pharma Becomes New Industry Supporter of the American Society of Anesthesiologists

30 March 2021

Publication of Annual Report and Financial Statements for the Year ended 31 December 2020

29 March 2021

Results for the Year ended 31 December 2020

18 February 2021

Change of EU Home Member State

28 January 2021

Acacia Pharma Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 
30 Minutes or Less

20 January 2021

Acacia Pharma Wins BEL Small Company of the Year for the Second Consecutive Year

15 December 2020

Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ 

09 October 2020

Acacia Pharma Completes Drawdown from €25 million Loan Facility from Cosmo Pharmaceuticals to Support US Launches of BARHEMSYS® and BYFAVO™

06 October 2020

Acacia Pharma Announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US

23 August 2020

BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV)

14 August 2020

Results of Placing

13 August 2020

Interim Results for the Six Months ended 30 June 2020

27 July 2020

Acacia Pharma Advances Preparations for US Launch of BARHEMSYS®

15 July 2020

Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

02 July 2020

Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation